ONSSI
ONSSI Corporation is a university-originated startup venture dedicated to accelerating the research and development of innovative therapeutic drugs for intractable diseases, aiming to deliver these medicines to patients as quickly as possible. Established in 2019 and recognized as an Iwate Medical University-certified venture in August 2023, the company focuses on novel gene therapies and antibody pharmaceuticals, emphasizing partnerships with other companies and universities to bring groundbreaking medicines to patients and their families.
Industries
Nr. of Employees
small (1-50)
Products
Viral-vector gene therapy candidate (SOCS3 expression)
Preclinical gene therapy approach using viral vectors to force expression of SOCS3 in tumor cells to inhibit constitutively active STAT3 signaling and produce antitumor effects.
Monoclonal antibody–drug conjugate development targeting tumor-enriched membrane antigen
Preclinical development of monoclonal antibodies linked to cytotoxic drugs directed against cell-surface antigens identified as overexpressed in certain cancers (example target: glypican family member identified by membrane proteomics).
質量分析計を用いたタンパク質解析受託サービス
質量分析計を用いたタンパク質解析受託サービスです。データ取得からデータ解析までリーズナブルな価格設定で実施いたします。
ショットガン解析
質量分析計を用いた網羅的なショットガンプロテオーム解析サービス。
サイトカインシグナル阻害分子を用いた新規遺伝子治療薬
アデノウイルスベクターを用いて癌細胞内でSOCS3を強制発現させ、Jak-Statシグナル伝達経路のStat3を制御することで抗腫瘍効果を得る新規遺伝子治療薬の開発。
がん細胞特異的抗原を標的とした抗体薬物複合体
定量的プロテオミクス手法により同定されたグリピカン-1（GPC1）を標的とする抗GPC1モノクローナル抗体を用いた抗体薬物複合体（ADC）の開発。
Viral-vector gene therapy candidate (SOCS3 expression)
Preclinical gene therapy approach using viral vectors to force expression of SOCS3 in tumor cells to inhibit constitutively active STAT3 signaling and produce antitumor effects.
Monoclonal antibody–drug conjugate development targeting tumor-enriched membrane antigen
Preclinical development of monoclonal antibodies linked to cytotoxic drugs directed against cell-surface antigens identified as overexpressed in certain cancers (example target: glypican family member identified by membrane proteomics).
質量分析計を用いたタンパク質解析受託サービス
質量分析計を用いたタンパク質解析受託サービスです。データ取得からデータ解析までリーズナブルな価格設定で実施いたします。
ショットガン解析
質量分析計を用いた網羅的なショットガンプロテオーム解析サービス。
サイトカインシグナル阻害分子を用いた新規遺伝子治療薬
アデノウイルスベクターを用いて癌細胞内でSOCS3を強制発現させ、Jak-Statシグナル伝達経路のStat3を制御することで抗腫瘍効果を得る新規遺伝子治療薬の開発。
がん細胞特異的抗原を標的とした抗体薬物複合体
定量的プロテオミクス手法により同定されたグリピカン-1（GPC1）を標的とする抗GPC1モノクローナル抗体を用いた抗体薬物複合体（ADC）の開発。
Services
In-gel digestion and LC-MS/MS identification of proteins from excised SDS-PAGE or 2D electrophoresis bands submitted by customers; results delivered by email.
Comprehensive proteome identification workflow including protein extraction, quantification, enzymatic digestion, nanoLC-MS/MS acquisition and data analysis to deliver lists of identified proteins.
Advisory service on sample-preparation methods, contamination control, staining protocols and appropriate consumables to optimize mass-spectrometry outcomes.
In-gel digestion and LC-MS/MS identification of proteins from excised SDS-PAGE or 2D electrophoresis bands submitted by customers; results delivered by email.
Comprehensive proteome identification workflow including protein extraction, quantification, enzymatic digestion, nanoLC-MS/MS acquisition and data analysis to deliver lists of identified proteins.
Advisory service on sample-preparation methods, contamination control, staining protocols and appropriate consumables to optimize mass-spectrometry outcomes.
Expertise Areas
- Proteomics analysis and biomarker discovery
- Mass-spectrometry-based analytical services
- Gene therapy development (viral vector-mediated)
- Antibody-drug conjugate discovery and development
Key Technologies
- NanoLC-MS/MS
- High-resolution tandem mass spectrometry
- HPLC for proteomics
- Shotgun (bottom-up) proteomics
News & Updates
Website Launch
The company's website was launched on May 1, 2020.
Website Launch
The company's website was launched on May 1, 2020.